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S U M M A R Y
Background: Japanese encephalitis virus (JEV) is endemic in Thailand and prevention strategies include
vaccination, vector control, and health education.
Methods: Between July 2003 and August 2005, we conducted hospital-based surveillance for encephalitis
at seven hospitals in Bangkok and Hat Yai. Serum and cerebrospinal (CSF) specimens were tested for
evidence of recent JEV infection by immunoglobulin M (IgM) enzyme-linked immunosorbent assay
(ELISA) and a plaque reduction neutralization test (PRNT).
Results: Of the 147 patients enrolled and tested, 24 (16%) had evidence of acute ﬂavivirus infection: 22
(15%) with JEV and two (1%) with dengue virus. Of the 22 Japanese encephalitis (JE) cases, 10 (46%) were
aged 15 years. The median length of hospital stay was 13 days; one 13-year-old child died. Ten percent
of encephalitis patients enrolled in Bangkok hospitals were found to have JEV infection compared to 28%
of patients enrolled in hospitals in southern Thailand (p < 0.01). Four (40%) of the 10 children with JE
were reported as being vaccinated.
Conclusions: JEV remains an important cause of encephalitis among hospitalized patients in Thailand.
The high proportion of JE among encephalitis cases is concerning and additional public health prevention
efforts or expanded vaccination may be needed.
Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
Contents lists available at ScienceDirect
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Japanese encephalitis virus (JEV), a mosquito-borne virus, is an
important cause of encephalitis in Asia with an estimated 50 000* Corresponding author. Tel.: +1 404 639 7883; fax: +1 404 639 3106.
E-mail address: SOlsen@cdc.gov (S.J. Olsen).
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doi:10.1016/j.ijid.2010.03.022cases of Japanese encephalitis (JE) and 10 000 deaths each year. JE
is a severe disease and up to 50% of personswho survive it can have
prolonged neurological or psychiatric sequelae.1 JE is endemic in
Thailand, with between 1500 and 2500 cases reported annually
throughout the 1970 s and 1980 s.2,3
To reduce the burden of disease, in 1973, the Thailand Ministry
of Public Health (MOPH) implemented a JE control program that
initially focused on vector control. In 1990, a locally producednal Society for Infectious Diseases.
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the routine immunization schedule.4 Children aged 1 to 3 years
receive two primary doses four weeks apart and then a booster
after one year.5 By the mid-1990 s, the JE control program was
multi-faceted and included education campaigns, vector control,
and vaccination.3 In 2003, a vaccination coverage survey con-
ducted in 12 provinces found that among children 2 to 3 years of
age, 92% and 87% had received their ﬁrst and second dose of JE
vaccine, respectively (Thailand MOPH, unpublished data). In 3- to
4-year-olds, the survey found 89%, 85%, and 62% coverage for doses
one, two, and three, respectively.
As a result of these interventions, over the past 20 years
Thailand has achieved dramatic reductions in the number of JE
cases reported nationally.6 Between 2002 and 2008, the number of
encephalitis cases reported nationally ranged from 297 to 418 per
year, representing a four- to eight-fold decrease from earlier
decades.7
In 2003, we conducted a rigorous prospective assessment of the
frequency of JEV as a cause of encephalitis in a country with good
JEV vaccination coverage. Our ﬁndings suggest that JEV remains a
relatively common cause of encephalitis in the two areas of
Thailand studied.
2. Methods
2.1. Case enrollment
Patients were identiﬁed from all wards at ﬁve hospitals in
Bangkok (Queen Sirikit National Institute of Child Health, Rajvithi
Hospital, Ramathibodi Hospital, Prasat Neurological Institute,
Phramongkutklao Hospital) and two in Hat Yai (Hat Yai Hospital
and Prince Songkhla University Hospital) between July 2003 and
August 2005. Inpatients meeting the following criteria were
approached for enrollment: (1) fever or hypothermia (i.e., history
of fever or documented temperature 38 8C or 35 8C); (2)
evidence of acute brain dysfunction (i.e., encephalopathy, central
neurological ﬁndings, or seizures) with onset 14 days prior to
admission; and (3) clinical indication for lumbar puncture as
determined by a staff physician. Eligible patients or their parent/
guardian were asked to provide informed consent.
For each consenting patient, the attending neurologist and a
research nurse used standardized forms to collect the following
information: demographics, clinical symptoms, results of imaging
studies, treatment prior to enrollment, exposures onemonth before
the onset, travel history, vaccination history, and signiﬁcant
medical/social history. In addition, the nurse recorded relevant
laboratory data obtained as part of the patient’s clinical care.
Cerebrospinal ﬂuid (CSF), saliva, oropharyngeal swab, urine, stool,
whole blood, and acute serum samples were collected from each
patient at admission. Patients who had been discharged were asked
to return for a convalescent visit 3 to 5 weeks after admission.
A case of encephalitis was deﬁned as a patient who met the
enrollment criteria and had neuroimaging (i.e., computed tomog-
raphy (CT) or magnetic resonance imaging (MRI)) or electroen-
cephalography (EEG) ﬁndings consistent with encephalitis, or CSF
pleocytosis (white blood cell (WBC) counts: 6 weeks old,
>14  106/l; >6 weeks old, >4  106/l).
The protocol was approved by the ethics committee of each
participating hospital, the Ethics Review Committee of the
Thailand Ministry of Public Health, and the Institutional Review
Board of the US Centers for Disease Control and Prevention (CDC).
2.2. Laboratory testing
Specimens were split prior to freezing and tested both at CDC
and the Thai National Institutes of Health (NIH). Serum and CSFsamples from patients enrolled in the study were tested at the
Arboviral Diseases Branch, CDC, Fort Collins, CO, USA. Specimens
were tested using JEV and dengue virus (DENV) immunoglobulinM
(IgM) capture enzyme-linked immunosorbent assays (ELISA).8
Specimens testing positive for JEV or DENV IgM antibodies in
serum or CSFwere tested for JEV and DENV neutralizing antibodies
by plaque reduction neutralization tests using a 90% cut-off value
(PRNT90).
9 For patients with serological evidence of recent DENV
infection, acute serum or CSF samples (i.e., collected 7 days after
symptom onset) were also evaluated using a reverse transcription
polymerase chain reaction (RT-PCR) for DENV RNA.10 The Thai NIH
conducted IgM ELISA for JEV on serum and CSF.11 These results
were compared to CDC laboratory results to evaluate in-country
diagnostics.
2.3. Case classiﬁcation
For the purpose of describing the epidemiology of hospitalized
patients with JEV infection, case status was determined based on
the CDC laboratory results. A conﬁrmed case of recent JEV infection
was deﬁned as the presence of (1) JEV IgM antibodies in CSF, or (2)
JEV IgM antibodies in serum with a JEV PRNT90 titer 20 and a JEV
PRNT90 to DENV PRNT90 titer ratio4. A probable case had JEV IgM
antibodies in serumwith a JEV PRNT90 titer20 but the JEV PRNT90
to DENV PRNT90 titer ratio was < 4. A non-JE case was deﬁned as a
patient who met the case deﬁnition for encephalitis and had a
serum or CSF specimen collected 10 or more days after fever onset
that tested negative at CDC for JEV IgM antibodies. Patients with
DENV infection were excluded from this non-JE case classiﬁcation.
A conﬁrmed case of recent DENV infection was deﬁned as the
presence of (1) DENV RNA in serum or CSF, or (2) DENV IgM
antibodies in serum with a DENV PRNT90 titer 20 and a DENV
PRNT90 to JEV PRNT90 titer ratio 4.
2.4. Statistical analysis
Frequencies were compared using Chi-square for dichotomous
variables and analysis of variance (ANOVA) for continuous
variables. A p-value of <0.05 was considered signiﬁcant. All
analyses were conducted using SPSS software (SPSS Inc., Chicago,
IL, USA). For computing test sensitivity and speciﬁcity, we used the
CDC assay as the gold standard. Results from the Thai NIH were
classiﬁed as JEV infection, not JEV infection, or not interpretable.
For the purposes of the comparison of results between the two
laboratories, we considered those marked by the Thai NIH as not
interpretable to be negative.
3. Results
Between July 2003 and August 2005, 150 hospitalized patients
met the case deﬁnition for acute encephalitis. Of these, 147 (98%)
had specimens available for testing at CDC. Evidence of recent
ﬂavivirus infection was identiﬁed in 24 (16%) patients: 22 with
JEV (16 conﬁrmed and six probable) and two with dengue (both
conﬁrmed). The proportion of encephalitis cases due to JEV varied
byhospital: 6/21 (29%) inHatYai, 5/18 (28%) in Prince Songkhla, 4/
15 (27%) in Prasat Neurological Institute, 1/6 (17%) in Rajvithi, 1/
11 (9%) in Phramongkutklao, 3/36 (8%) in Ramathibodi, and 2/40
(5%) in Queen Sirikit National Institute of Child Health. Ten
percent of encephalitis patients enrolled in Bangkok hospitals
were found to have JEV infection compared to 28% of patients
enrolled in hospitals in southern Thailand (p < 0.01). There were
107 patients who had adequate testing to rule out JEV infection
and who were classiﬁed as non-JE cases. The remaining 16
patients did not have adequate specimens to either rule in or rule
out JEV infection.
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Fig. 1. Percent and cumulative percent of patients with Japanese encephalitis virus by age group.
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3.1.1. Basic demographics
Of the 22 cases with JEV infection, 14 (64%) were male and the
median age was 19 years (range 6 months to 57 years). Overall, 10
(46%) of the JE patients were aged<15 years and another ﬁve (23%)
patients were aged 15–19 years (Figure 1). Ten (46%) were
reported from the hospitals in southern Thailand and 12 (54%)
from the hospitals in Bangkok. Patients with JEV infection were
identiﬁed throughout the year, with a peak from March through
June (Figure 2). The numbers were too small to assess seasonal
variability by site and year. Fourteen (64%) patients with JEV
infection reported living in a rural area (farm or countryside) in the
past three months; two patients reported residing in Bangkok
Provincewhen illness began. Patientswith conﬁrmed and probable
JEV infection were similar with respect to age (19 years vs. 24
years, p = 0.6) and male sex (69% vs. 50%, p = 0.6).
3.1.2. Clinical characteristics and outcomes
Among the 22 patients with JEV infection, 21 (95%) had altered
mental status, including seven (32%) who were comatose. Fifteen
(68%) patients had stiff neck, and 10 (45%) had seizures, including
eight (80%) of the 10 children aged<15 years. Of the 22 JE patients,
21 (95%) had CSF pleocytosis; 11 (50%), including the one patient
without pleocytosis, had abnormal neuroimaging, and three (14%)
had an abnormal EEG. The median CSF WBC count was 66 106/l
(range 0–690 106/l), protein was 70mg/dl (range 20–218 mg/dl),
[(Fig._2)TD$FIG]
Fig. 2. Seasonality of Japanese encephalitis in patients by site of enrollment
(Bangkok versus southern Thailand), July 2003 through August 2005.and glucose was 62mg/dl (range 1–138 mg/dl). Of all 22 patients,
seven (32%) had an elevated CSF opening pressure (>60 mm
for children and >200 mm for adults). The median length of
hospital stay was 13 days (range 4–173 days). One (5%) JE
patient, aged 13 years, died. Of the 21 surviving patients, nine were
seen after hospital discharge and one (11%) reported poor cognitive
recovery.
JE patients were signiﬁcantly more likely to present with stiff
neck or focal neurological signs compared to other encephalitis
patients without JE (Table 1). No other differences were identiﬁed
in patient demographics, clinical characteristics, or outcomes.
3.1.3. Vaccination history
Four (18%) JE patients reported having received JE vaccine. Two
children, both 2 years of age, had each received two doses of JE
vaccine with the last dose administered approximately one year
prior to their illness. A 6-year-old had received one dose of JE
vaccine almost ﬁve years before illness onset. An 18-year-old also
reported being vaccinated but no dates were given. Of the
remaining JE patients, 12 (54%) had not received JE vaccine and
six (27%) did not know their vaccination status. Given that country-
wide childhood vaccination began in 2000, two of the 12
unvaccinated persons (a 3-year-old and a 7-year-old) were likely
eligible for JE vaccine as part of the national programbetween 2000
and 2005.
3.1.4. Laboratory comparison of JE testing
Of the 147 encephalitis patients tested at CDC, 146 (99%) had
specimens available for testing at the Thai NIH. Of the 22 JEV
infections identiﬁed at CDC, 21 (95%) were also identiﬁed as recent
JEV infections by the Thai NIH. Of the 124 JEV-negative infections,
all were negative or not interpretable at the Thai NIH.
3.2. Dengue fever
Two patients meeting the encephalitis case deﬁnition had
evidence of recent DENV infection. The ﬁrst was a 4-year-old girl
who presented with a temperature of 39.6 8C and CSF with a WBC
count of 0  106/l, 31 mg/dl protein, and 216 mg/dl glucose and a
Glasgow coma score of 4. The patient experienced seizures and
focal neurological signs, and presented to hospital in a coma.
No further information was available to suggest evidence of
hemorrhage or shock. An EEG was abnormal and demonstrated
asymmetrical features; neuroimaging was not done. Acute and
convalescent sera were collected at 5 days and 30 days after illness
onset. DENV IgM antibodies were identiﬁed in both specimens and
Table 1
Comparison of characteristics of patients with encephalitis with and without laboratory-conﬁrmed Japanese encephalitis
Characteristic Patients with Japanese
encephalitis (N=22), n (%)
Patients without Japanese
encephalitis (N=107), n (%)
p-Value
Demographic
Male 14 (64) 57 (53) 0.37
Median age (range) 19 years (0–57) 11 years (0–83) 0.81
Currently live in rural areac 14 (64) 51 (48) 0.19
Clinical
Altered mental status 21 (95) 86 (80) 0.07
Stiff neck 15 (68) 38 (36) <0.01a
Headache 14 (64) 50 (47) 0.22
Personality change 12 (55) 40 (37) 0.05
Focal neurological signs 11 (50) 33 (31) 0.01a
Seizure 10 (45) 49 (46) 0.97
Coma 7 (32) 12 (11) 0.05
Median CSF WBC (range)b 66106/l (0–690) 22106/l (0–4150) 0.83
Outcome
Median length of hospital stay (range) 13 days (4–173) 18 days (2–180) 0.17
Died 1 (5) 4 (4) 0.86
Exposure
Mosquito bite 19 (86) 95 (89) 0.75
JE vaccine 4d (18) 39e (36) 0.08
CSF, cerebrospinal ﬂuid; WBC, white blood cell count; JE, Japanese encephalitis.
a Current deﬁned as in the past 3 months.
b One patient with JE and two patients without JE were missing CSF WBC.
c Signiﬁcant at p < 0.05.
d Two persons had one dose; two persons had two doses.
e Thirty-ﬁve persons had two or more doses.
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acute and convalescent serum. CSF was not available for DENV
antibody testing and there was no remaining serum for DENV RT-
PCR. The second patientwas a 12-year-old boywho presentedwith
a temperature of 39.0 8C and CSF with a WBC count of 7  106/l,
25 mg/dl protein, and 89 mg/dl glucose and a Glasgow coma score
of 15. Before hospitalization, the patient experienced personality
change. EEG was normal and neuroimaging was not done. Acute
and convalescent sera were drawn at 3 days and 33 days after
illness onset. DENV IgM antibodies were identiﬁed in both
specimens and DENV neutralizing antibody titers increased
four-fold between the acute and convalescent serum. The acute
serumwas positive by RT-PCR for DENV RNA. CSFwas not available
for DENV antibody or RT-PCR testing.
4. Discussion
JEV remains an important cause of encephalitis in Thailand.
Although vector control efforts and vaccine introduction in 2000
have resulted in a reduced disease burden, the data presented here
suggest that JE continues to be a public health concern, causing an
estimated 15% of hospitalized encephalitis cases, and affecting not
only children but also adolescents and adults.
Clinical differentiation of the causes of encephalitis can be
challenging, and JE presents like encephalitis ofmany other causes.
In this study, patients with JE were signiﬁcantly more likely to
present with stiff neck or focal neurological signs compared to
patients with encephalitis not due to JEV. These ﬁndings might
help guide clinicians in the diagnosis.
Interestingly, in this study of hospitalized patients, the
proportion of encephalitis patients with JEV infection was
signiﬁcantly higher among the southern hospitals than those in
Bangkok. This difference cannot be wholly explained by vaccine
introduction because it was introduced the same year, 2000, in
Bangkok and suburbs, as well as the southern provinces. It may be
that civil unrest in southern Thailand contributed to lower
vaccination uptake in the population, although vaccine coverage
surveys in a nearby province do not support that hypothesis. The
difference may instead reﬂect other factors, such as ecologicalvariability in JEV or vector density between areas, or relative
differences in other more prevalent causes of encephalitis.
Similar to recent studies in Nepal demonstrating a large
proportion of JE in adults,12,13 55% of our patients with JE were
aged 15 years or older. In Thailand, nationwide JE vaccination
began in 2000, and JE vaccine coverage studies conducted in 2003
showed high coverage of the ﬁrst two doses. These studies
included two provinces neighboring our study sites: Nonthaburi
which borders Bangkok and Phatthalung which borders Songkhla.
In 2006, only persons between the ages of 1 and 6 years should
have been vaccinated. There were ﬁve patients with JEV in this
study who should have been vaccinated and three of them were,
although none received all three doses of the vaccine. The majority
of patients in this study who developed JEV infection were over 6
years old and therefore not vaccinated. Additional data, such as
incidence to determine the burden of JEV disease in Thailand, may
help to determinewhether additional strategies, such as a catch-up
campaign to vaccinate adolescents and adults, should be consid-
ered to reduce disease in adults.
There were two patients who had convincing laboratory
evidence of recent dengue infection, but neither had convincing
evidence of central nervous system inﬂammation. Although the
role of DENV in encephalitis is still controversial, a few studies have
documented neurological ﬁndings.14,15 In locations like Thailand
where JEV and DENV are endemic, it is prudent to test specimens
for both viruses.
Historically, JE is thought to be a disease largely transmitted in
rural areas and our ﬁndings support that claim; the majority of
patients reported living in a rural area in the three months before
illness. However, there is increased interest in the importance of
urban or peri-urban environments, where large populations with
high density reside. A study by Gingrich and colleagues in
suburban Bangkok found that transmission can be sustained if
conditions are right.16 In our study, only two patients with JEV
infection were reportedly in Bangkok proper, although it is
impossible to know precisely where transmission occurred.
Although Thailand’s strategy to combat JEV is multifaceted, a
core component is vaccination using a locally produced, affordable
vaccine. With the development of new JEV vaccines, such as the
S.J. Olsen et al. / International Journal of Infectious Diseases 14 (2010) e888–e892e892live-attenuated SA 14–14–2 vaccine, and a World Health
Organization recommendation to gradually replace the mouse-
brain derived vaccine with new vaccines, Thailand may reconsider
the current strategy.5,17 Human vaccination will continue to be
central to any prevention efforts since the complexity of
controlling JEV transmission cycles makes elimination unlikely.18
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